Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect
Today, Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound® (tirzepatide) KwikPen® for single-patient use will be available at LillyDirect® and major pharmacies nationwide, starting at $299 per month for the 2.5 mg dose.
